Clinical Trial Update: Safety, Tolerability, PK and PD of BI 655075 and Establishment of BI 655075 Dose(s) Effective to Reverse Prolongation of Blood Coagulation Time by Dabigatran [Phase 1]

View source ↗

Summary

A Phase 1 trial assesses safety, tolerability, pharmacokinetics and pharmacodynamics of BI 655075 (idarucizumab) and establishes dose(s) effective at reversing …

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Hemorrhage

Drugs mentioned

• Praxbind (Idarucizumab)

Snippet

Sponsor: Boehringer Ingelheim | Conditions: Hemorrhage | Phase 1 | Status: COMPLETED | Results posted: 2016-02-11